Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA064679-03
Application #
2107310
Study Section
Experimental Immunology Study Section (EI)
Project Start
1994-09-30
Project End
1997-08-31
Budget Start
1996-09-01
Budget End
1997-08-31
Support Year
3
Fiscal Year
1996
Total Cost
Indirect Cost

  Institution

Name
University of Texas Sw Medical Center Dallas
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
City
Dallas
State
TX
Country
United States
Zip Code
75390

  Publications

Ghetie, Maria-Ana; Marches, Radu; Kufert, Stephanie et al. (2004) An anti-CD19 antibody inhibits the interaction between P-glycoprotein (P-gp) and CD19, causes P-gp to translocate out of lipid rafts, and chemosensitizes a multidrug-resistant (MDR) lymphoma cell line. Blood 104:178-83
Meng, Ruiqi; Smallshaw, Joan E; Pop, Laurentiu M et al. (2004) The evaluation of recombinant, chimeric, tetravalent antihuman CD22 antibodies. Clin Cancer Res 10:1274-81
Ghetie, M A; Bright, H; Vitetta, E S (2001) Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 97:1392-8
Ghetie, M A; Ghetie, V; Vitetta, E S (1999) Anti-CD19 antibodies inhibit the function of the P-gp pump in multidrug-resistant B lymphoma cells. Clin Cancer Res 5:3920-7
Thrush, G R; Lark, L R; Clinchy, B C et al. (1996) Immunotoxins: an update. Annu Rev Immunol 14:49-71
Uhr, J W; Marches, R; Racila, E et al. (1996) Role of antibody signaling in inducing tumor dormancy. Adv Exp Med Biol 406:69-74
Ghetie, V; Engert, A; Schnell, R et al. (1995) The in vivo anti-tumor activity of immunotoxins containing two versus one deglycosylated ricin A chains. Cancer Lett 98:97-101